Compare BBLG & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBLG | ONCO |
|---|---|---|
| Founded | 2004 | 2018 |
| Country | United States | United States |
| Employees | 2 | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5M | 2.8M |
| IPO Year | N/A | 2021 |
| Metric | BBLG | ONCO |
|---|---|---|
| Price | $0.94 | $0.89 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 31.0K | ★ 225.7K |
| Earning Date | 05-13-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.80 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $815,371.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.83 | $0.09 |
| 52 Week High | $4.13 | $6.73 |
| Indicator | BBLG | ONCO |
|---|---|---|
| Relative Strength Index (RSI) | 44.04 | 52.11 |
| Support Level | N/A | $0.64 |
| Resistance Level | $1.38 | $0.94 |
| Average True Range (ATR) | 0.08 | 0.11 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 60.00 | 69.17 |
Bone Biologics Corp a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. It is a clinical-stage entity. The production and marketing of its products and ongoing research and development activities are subject to extensive regulation by numerous governmental authorities in the United States.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.